Johnson & Johnson stock outperforms competitors despite losses on the day
Johnson & Johnson closed $25.19 below its 52-week high ($168.85), which the company reached on September 4th.
Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study
Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.
Mike Johnson narrowly reelected House speaker on first ballot: How the news unfolded
Republican Mike Johnson won reelection to the House speakership on a first ballot, pushing past GOP hard-right holdouts and ...